ONCOGENE 润色咨询

ONCOGENE

出版年份：1987 年文章数：9343 投稿命中率： 开通期刊会员，数据随心看

出版周期：Weekly 自引率：3.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-11-30 ms2000001788822132 来自上海

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤
    经验分享：转投oncogene
    送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。
    三审是一周内结束，已accept，很开心，满意，速度很快。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-11-01 blending glue 来自上海

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：现在等外审结果

    9

    展开9条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-11-28 147f2cd9m92暂无昵称 来自北京

    即时影响因子已经六分多了，新的影响因为应该会涨

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-11-22 雨落殇殇 来自云南省

    偏重的研究方向：肿瘤;cancer biology;Molecular cancer
    经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-06-21 1811e984f8m 来自安徽省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-06-25 zkk 来自广东省

    刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2019-09-23 默默0518

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享：Decision Made 23rd Sep 19
    Editor in Chief Decision Complete 22nd Sep 19
    Manuscript Decision complete 22nd Sep 19
    Editor Decision Complete 22nd Sep 19
    EIC Decision Started 20th Sep 19
    Editor Review Completed 20th Sep 19
    Receiving Editor Review Started 20th Sep 19
    Review Complete 20th Sep 19
    All Reviewers Assigned 30th Aug 19
    Review Started 30th Aug 19
    Under Consdieration 22nd Jul 19
    Contacting Reviewers 22nd Jul 19
    Reviewers Assigned 22nd Jul 19
    Waiting for Potential Reviewer Assignment 5th Jul 19
    Monitoring Editor Assigned 5th Jul 19
    Potential Monitoring Editor Assigned 5th Jul 19
    Under Consideration 4th Jul 19
    Initial Manuscript Review Completed 4th Jul 19
    Initial Manuscript Review Started 27th Jun 19
    Senior Editor Assigned 27th Jun 19
    26th Jun 19
    Editor Assigned 26th Jun 19
    Waiting for Editor Assignment 26th Jun 19
    Initial QC Started 26th Jun 19
    Author Approved Converted Files 26th Jun 19
    Submission 25th Jun 19
    供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-11-04 ms1000001788822131 来自上海

    审稿速度:6.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤
    经验分享：送审很快
    一轮大概两个月
    第二轮遇到假，毕竟慢，耗时一个月
    审稿人只提了几个小问题
    三审是一周内结束，这速度很满意了

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-09-11 沧海医僧笑 来自重庆

    submit成功，接好运

    12

    展开12条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2240110, encodeId=6dca22401103d, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：转投oncogene<br>送审速度很快，第一轮大概两个对月，第二轮恰逢节假日，不知道什么原因慢了一些，用了一个月零4天，审稿人很认真，提了一些细节上的问题。<br>三审是一周内结束，已accept，很开心，满意，速度很快。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822132, createdTime=Sat Nov 30 21:48:13 CST 2024, time=2024-11-30, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234645, encodeId=bbca22346451c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：现在等外审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9f21960859, createdName=blending glue, createdTime=Fri Nov 01 22:36:59 CST 2024, time=2024-11-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2239713, encodeId=fed22239e138a, content=即时影响因子已经六分多了，新的影响因为应该会涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39875256687, createdName=147f2cd9m92暂无昵称, createdTime=Thu Nov 28 13:24:22 CST 2024, time=2024-11-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238456, encodeId=eac722384562e, content=偏重的研究方向：肿瘤;cancer biology;Molecular cancer<br>经验分享：请问大家，投稿后两天变成了editor in chief decision complete，这是没戏了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Fri Nov 22 16:03:34 CST 2024, time=2024-11-22, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2210939, encodeId=186f2210939d7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2022-2023年撤稿25篇，expression of concern 5篇，2023影响因子跌倒了6.9。2024至今撤稿7篇，expression of concern 3篇，目前即时影响因子只有2.69，明年的IF大概率继续下跌。当年仅次于cancer research的学术杂志，混成如此模样，感觉编辑委员会应该大换血了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Fri Jun 21 08:39:29 CST 2024, time=2024-06-21, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2211529, encodeId=613e221152916, content=刚投了一篇送外审，影响因子就跌到7以下了，这杂志比起cancer letters怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=099c1677309, createdName=zkk, createdTime=Tue Jun 25 11:01:53 CST 2024, time=2024-06-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=576790, encodeId=11365e679055, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：Decision Made 23rd Sep 19 <br> Editor in Chief Decision Complete 22nd Sep 19 <br> Manuscript Decision complete 22nd Sep 19 <br> Editor Decision Complete 22nd Sep 19 <br> EIC Decision Started 20th Sep 19 <br> Editor Review Completed 20th Sep 19 <br> Receiving Editor Review Started 20th Sep 19 <br> Review Complete 20th Sep 19 <br> All Reviewers Assigned 30th Aug 19 <br> Review Started 30th Aug 19 <br> Under Consdieration 22nd Jul 19 <br> Contacting Reviewers 22nd Jul 19 <br> Reviewers Assigned 22nd Jul 19 <br> Waiting for Potential Reviewer Assignment 5th Jul 19 <br> Monitoring Editor Assigned 5th Jul 19 <br> Potential Monitoring Editor Assigned 5th Jul 19 <br> Under Consideration 4th Jul 19 <br> Initial Manuscript Review Completed 4th Jul 19 <br> Initial Manuscript Review Started 27th Jun 19 <br> Senior Editor Assigned 27th Jun 19 <br> 26th Jun 19 <br> Editor Assigned 26th Jun 19 <br> Waiting for Editor Assignment 26th Jun 19 <br> Initial QC Started 26th Jun 19 <br> Author Approved Converted Files 26th Jun 19 <br> Submission 25th Jun 19 <br> 供参考，经历89天，被拒了，2个reviewer，其中一个比较nice提了几个问题，另外一个reviewer只有2句话。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4562222672, createdName=默默0518, createdTime=Mon Sep 23 19:26:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2235173, encodeId=06b222351e3d7, content=审稿速度:6.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：送审很快<br>一轮大概两个月<br>第二轮遇到假，毕竟慢，耗时一个月<br>审稿人只提了几个小问题<br>三审是一周内结束，这速度很满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822131, createdTime=Mon Nov 04 23:25:39 CST 2024, time=2024-11-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2225136, encodeId=73b022251366b, content=submit成功，接好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Sep 11 01:18:58 CST 2024, time=2024-09-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2228043, encodeId=45be2228043d0, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤<br>经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIIzJXIAHCPG4r7x2oePkLgXIiaZG61O1w1Q6eSBSnPH2CObSy9Q7NyseSuEiclsGhVy0LpCO8Qvm8Q/132, createdBy=30872262367, createdName=Scarlettt, createdTime=Fri Sep 27 20:15:08 CST 2024, time=2024-09-27, status=1, ipAttribution=慕尼黑)]
    2024-09-27 Scarlettt 来自慕尼黑

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向：肿瘤
    经验分享：CCR大修被拒后转投Oncogene，秒速送审，第一轮大概两个月，第二轮恰逢暑假，估计审稿人度假去了，花了一个月，审稿人只提了一些细节上的小问题，三审是一周内结束，已原则性accept，速度很快。

    0

共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分